P/E ratio for Curis (CRIS)

P/E ratio history for Curis from 2001 to 2023

PE ratio at the end of each year

P/E ratio for similar companies or competitors

Company	P/E ratio	P/E ratio differencediff.	Country
Exelixis EXEL	123	-30,086.34%	🇺🇸 USA
Emergent BioSolutions EBS	-0.7781	89.79%	🇺🇸 USA
Spectrum Pharmaceuticals SPPI	-2.86	597.83%	🇺🇸 USA
Celldex Therapeutics CLDX	-10.9	2,564.63%	🇺🇸 USA
Pfizer PFE	13.5	-3,395.32%	🇺🇸 USA
Bristol-Myers Squibb BMY	14.7	-3,677.44%	🇺🇸 USA
Cel-Sci CVM	-0.7851	91.48%	🇺🇸 USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.